Csaba Szántai-Kis

743 total citations
24 papers, 423 citations indexed

About

Csaba Szántai-Kis is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Csaba Szántai-Kis has authored 24 papers receiving a total of 423 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Infectious Diseases. Recurrent topics in Csaba Szántai-Kis's work include HER2/EGFR in Cancer Research (5 papers), Tuberculosis Research and Epidemiology (4 papers) and Computational Drug Discovery Methods (3 papers). Csaba Szántai-Kis is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Tuberculosis Research and Epidemiology (4 papers) and Computational Drug Discovery Methods (3 papers). Csaba Szántai-Kis collaborates with scholars based in Hungary, Germany and United Kingdom. Csaba Szántai-Kis's co-authors include László Őrfi, Gÿorgý Kéri, Dániel Erös, János Pató, István Kövesdi, Ferenc Baska, Ruben C. Hartkoorn, Zoltán Greff, István Szabadkai and Stewart T. Cole and has published in prestigious journals such as PLoS ONE, Epilepsia and European Journal of Medicinal Chemistry.

In The Last Decade

Csaba Szántai-Kis

24 papers receiving 415 citations

Peers

Countries citing papers authored by Csaba Szántai-Kis

Since Specialization

Citations

This map shows the geographic impact of Csaba Szántai-Kis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Csaba Szántai-Kis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Csaba Szántai-Kis more than expected).

Fields of papers citing papers by Csaba Szántai-Kis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Csaba Szántai-Kis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Csaba Szántai-Kis. The network helps show where Csaba Szántai-Kis may publish in the future.

Co-authorship network of co-authors of Csaba Szántai-Kis

This figure shows the co-authorship network connecting the top 25 collaborators of Csaba Szántai-Kis. A scholar is included among the top collaborators of Csaba Szántai-Kis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Csaba Szántai-Kis. Csaba Szántai-Kis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases 2019 ·European Journal of Medicinal Chemistry ·Ferenc Baska, (unknown), (unknown), Zoltán Nemes, Judit Dobos, Csaba Szántai-Kis, Eszter Szabó, Gábor Szénási, László Dézsi, Péter Hamar, Mihály Cserepes, József Tóvári, Rita Garamvölgyi, (unknown), László Őrfi	12
2	Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters 2018 ·PLoS ONE ·(unknown), Szilárd Tóth, (unknown), (unknown), István Szabadkai, Ferenc Baska, Csaba Szántai-Kis, Ruben C. Hartkoorn, (unknown), Balázs Sarkadi, Gergely Szakács, László Őrfi, Valakunja Nagaraja, Sean Ekins, Ágnes Telbisz	6
3	Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), M. BALOGH, (unknown), (unknown), (unknown), Judit Dobos, (unknown), Zoltán Horváth, Eszter Illyés, (unknown), (unknown), Csaba Szántai-Kis, Bálint Szokol, László Őrfi	19
4	Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML 2018 ·Bioorganic & Medicinal Chemistry Letters ·Zoltán Nemes, Krisztina Takács‐Novák, Gergely Völgyi, Klára Valkó, Szabolcs Béni, Zoltán Horváth, Bálint Szokol, (unknown), Judit Dobos, Csaba Szántai-Kis, Eszter Illyés, (unknown), Robbert J. Kok, László Őrfi	8
5	Discovery and optimization of novel benzothiophene-3-carboxamides as highly potent inhibitors of Aurora kinases A and B 2018 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Bálint Szokol, István Szabadkai, (unknown), (unknown), (unknown), (unknown), (unknown), Eszter Illyés, Csaba Szántai-Kis, (unknown), (unknown), László Őrfi	4
6	Development of a 3D Tissue Culture–Based High-Content Screening Platform That Uses Phenotypic Profiling to Discriminate Selective Inhibitors of Receptor Tyrosine Kinases 2016 ·SLAS DISCOVERY ·Tijmen H. Booij, (unknown), Kuan Yan, Csaba Szántai-Kis, Bálint Szokol, László Őrfi, Bob van de Water, Gÿorgý Kéri, Leo Price	18
7	Design and synthesis of new imidazo[1,2- a ]pyridine and imidazo[1,2- a ]pyrazine derivatives with antiproliferative activity against melanoma cells 2015 ·European Journal of Medicinal Chemistry ·Rita Garamvölgyi, Judit Dobos, (unknown), (unknown), Eszter Illyés, Ferenc Baska, (unknown), István Szabadkai, Csaba Szántai-Kis, Gÿorgý Kéri, László Őrfi	31
8	Novel compounds reducing IRS-1 serine phosphorylation for treatment of diabetes 2015 ·Bioorganic & Medicinal Chemistry Letters ·Laura Simon‐Szabó, (unknown), Zoltán Greff, (unknown), (unknown), (unknown), Csaba Szántai-Kis, Tibor Vántus, József Mandl, Gábor Bánhegyi, István Vályi‐Nagy, László Őrfi, Axel Ullrich, Miklós Csala, Gÿorgý Kéri	11
9	Lead selection and characterization of antitubercular compounds using the Nested Chemical Library 2015 ·Tuberculosis ·(unknown), János Pató, Rita Székely, Ruben C. Hartkoorn, (unknown), László Őrfi, Csaba Szántai-Kis, Katarı́na Mikus̃ová, Zuzana Svetlíková, Jana Korduláková, Valakunja Nagaraja, Adwait Anand Godbole, Natassja G. Bush, Frédéric Collin, Anthony Maxwell, Stewart T. Cole, Gÿorgý Kéri	25
10	Targeting Vascular Endothelial Growth Factor Receptor 2 and Protein Kinase D1 Related Pathways by a Multiple Kinase Inhibitor in Angiogenesis and Inflammation Related Processes In Vitro 2015 ·PLoS ONE ·Attila Varga, (unknown), Zoltán Greff, Krisztina Futosi, Tamás Németh, Laura Simon‐Szabó, Krisztina Kerekes, Csaba Szántai-Kis, (unknown), (unknown), Gábor Borbély, Anna Erdei, Attila Mócsai, Gÿorgý Kéri, Tibor Vántus	9
11	Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors 2014 ·Current Medicinal Chemistry ·Ferenc Baska, István Szabadkai, (unknown), (unknown), Csaba Szántai-Kis, (unknown), Rita Garamvölgyi, Z. Nemes, Lars Neumann, Robert Torka, A. Ullrich, Gÿorgý Kéri, László Őrfi	10
12	Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors 2014 ·ACS Medicinal Chemistry Letters ·Bálint Szokol, (unknown), (unknown), Ferenc Baska, Csaba Szántai-Kis, Zoltán Greff, (unknown), (unknown), (unknown), Robert Torka, Axel Ullrich, László Őrfi, Tibor Vántus, Gÿorgý Kéri	12
13	Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing 2013 ·Current Medicinal Chemistry ·Han Kiat Ho, (unknown), (unknown), Emily M. Pang, Csaba Szántai-Kis, (unknown), (unknown), Zoltán Greff, (unknown), (unknown), István Szabadkai, Bálint Szokol, Ferenc Baska, László Őrfi, A. Ullrich, Gÿorgý Kéri, Boon Tin Chua	12
14	Protein kinase inhibitor as a potential candidate for epilepsy treatment 2011 ·Epilepsia ·Zita Gajda, Rita Maszlag-Török, Zoltán Horváth, Csaba Szántai-Kis, László Őrfi, Gÿorgý Kéri, Magdolna Szente	6
15	Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection 2011 ·Current Medicinal Chemistry ·Gábor Németh, Zoltán Varga, Zoltán Greff, (unknown), (unknown), Csaba Szántai-Kis, Ferenc Baska, Ágnes Gyuris, (unknown), (unknown), János Minárovits, (unknown), László Őrfi	29
16	Leads for antitubercular compounds from kinase inhibitor library screens 2010 ·Tuberculosis ·Sophie Magnet, Ruben C. Hartkoorn, Rita Székely, János Pató, James A. Triccas, Patricia Schneider, Csaba Szántai-Kis, László Őrfi, Marc Chambon, Damiano Banfi, (unknown), Gerardo Turcatti, Gÿorgý Kéri, Stewart T. Cole	84
17	Structure – Activity Relationships of PDE5 Inhibitors (Supporting Material) 2008 ·Current Medicinal Chemistry ·Dániel Erös, Csaba Szántai-Kis, Róbert Kiss, (unknown), (unknown), István Kövesdi, László Őrfi	13
18	Prediction Oriented QSAR Modelling of EGFR Inhibition 2006 ·Current Medicinal Chemistry ·Csaba Szántai-Kis, István Kövesdi, Dániel Erös, (unknown), A. Ullrich, Gÿorgý Kéri, László Őrfi	11
19	Comparison of Predictive Ability of Water Solubility QSPR Models Generated by MLR, PLS and ANN Methods 2004 ·Mini-Reviews in Medicinal Chemistry ·Dániel Erös, Gÿorgý Kéri, István Kövesdi, Csaba Szántai-Kis, György Mészáros, László Őrfi	31
20	Validation subset selections for extrapolation oriented QSPAR models 2003 ·Molecular Diversity ·Csaba Szántai-Kis, István Kövesdi, Gÿorgý Kéri, László Őrfi	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact